Haisheng Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Haisheng Zhou has a total of 124 co-authors. Here are the top co-authors by number of shared publications:
Dandan Zang
Center for Scientific Research, AHMU, Hefei, China
7 shared publicationsDeping Xu
Department of Biochemistry and Molecular Biology, Anhui Medical University, Hefei, China
7 shared publicationsChunlin Cai
Department of Pathophysiology, AHMU, Hefei, China
6 shared publicationsKainan Liao
Department of Biochemistry and Molecular Biology, Anhui Medical University (AHMU), Hefei, China
6 shared publicationsLinzi Han
Department of Biochemistry and Molecular Biology, Anhui Medical University, Hefei, China
4 shared publicationsQiantong Xiang
Department of Dermatology The Affiliated Hefei Hospital of Anhui Medical University Hefei China
4 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9443
Endocrine Signaling and Tissue Remodeling in Gynecomastia: Implications for Treatment Response
To critically synthesize evidence on treatment response in gynecomastia using a framework that distinguishes biological response, structural response, and patient-important benefit. We searched PubMed, PubMed Central, and targeted journals through 11 September 2026. Priority was given to gynecomastia-specific human studies; evidence from other breast systems, animal models, and general biomarker methodology was treated as indirect. The randomized anastrozole trial showed an endocrine effect but did not demonstrate superiority over placebo on the prespecified structural endpoint. Receptor expression in surgical specimens provides biological plausibility but does not establish receptor functionality, endocrine dependence, or predictive value. Stromal composition may influence lesion regression, but this remains a hypothesis requiring direct testing. Ultrasonography and elastography may support pretreatment characterization, but current studies do not validate imaging features as surrogates for fibrosis or endocrine responsiveness. Gynecomastia-derived organoids offer a disease-relevant model for functional studies, although donor numbers are small and endocrine responsiveness, cellular representativeness, and reproducibility across patients require further evaluation remain uncertain. Biological response, structural response, and patient-important benefit need not occur together or in a fixed sequence. Further research should link tissue and model findings to pretreatment markers, compare treatment benefits, and establish clinical utility before marker-guided care.
- 23 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9443
Open AccessEndocrine Signaling and Tissue Remodeling in Gynecomastia: Implications for Treatment Response
To critically synthesize evidence on treatment response in gynecomastia using a framework that distinguishes biological response, structural response, and patient-important benefit. We searched PubMed, PubMed Central, and targeted journals through 11 September 2026. Priority was given to gynecomastia-specific human studies; evidence from other breast systems, animal models, and general biomarker methodology was treated as indirect. The randomized anastrozole trial showed an endocrine effect but did not demonstrate superiority over placebo on the prespecified structural endpoint. Receptor expression in surgical specimens provides biological plausibility but does not establish receptor functionality, endocrine dependence, or predictive value. Stromal composition may influence lesion regression, but this remains a hypothesis requiring direct testing. Ultrasonography and elastography may support pretreatment characterization, but current studies do not validate imaging features as surrogates for fibrosis or endocrine responsiveness. Gynecomastia-derived organoids offer a disease-relevant model for functional studies, although donor numbers are small and endocrine responsiveness, cellular representativeness, and reproducibility across patients require further evaluation remain uncertain. Biological response, structural response, and patient-important benefit need not occur together or in a fixed sequence. Further research should link tissue and model findings to pretreatment markers, compare treatment benefits, and establish clinical utility before marker-guided care.
- Open Access
- 26 June 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
GPR107 promotes autophagy secretion in psoriatic keratinocytes by inhibiting BECN1 K48-linked ubiquitination
Psoriasis is a chronic inflammatory skin disease driven by excessive proliferation and aberrant differentiation of keratinocytes. Autophagy-based unconventional secretory pathway (secretory autophagy) plays key roles in regulating cell proliferation and autosecretion in psoriatic keratinocytes; however, their upstream regulators remain poorly defined. The orphan G protein-coupled receptor 107 (GPR107) mediates signal transduction via clathrin-dependent endocytosis. Here, we report that upregulation of GPR107 in psoriatic keratinocytes promotes both cell proliferation and the secretion of chemokines and antimicrobial peptides through BECN1-dependent autophagy. Mechanistically, internalized GPR107 activates the β-arrestin/ERK/NF-κB pathway. This activation not only drives the direct transcription of inflammatory factors but also negatively regulates the expression of E3-ubiquitin ligase CUL3. The reduction of CUL3 decreases K48-linked ubiquitination at K206 of BECN1, preventing its proteasomal degradation. Stabilization of BECN1 facilitates secretory autophagy in psoriatic keratinocytes, further enhancing their proliferation and inflammatory responses. These findings highlight a novel function of GPR107 in psoriasis, and suggest that the integrated β-arrestin/ERK/NF-κB/CUL3/BECN1 axis may serve as a potential therapeutic target for this disease.
- 26 June 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Open AccessGPR107 promotes autophagy secretion in psoriatic keratinocytes by inhibiting BECN1 K48-linked ubiquitination
Psoriasis is a chronic inflammatory skin disease driven by excessive proliferation and aberrant differentiation of keratinocytes. Autophagy-based unconventional secretory pathway (secretory autophagy) plays key roles in regulating cell proliferation and autosecretion in psoriatic keratinocytes; however, their upstream regulators remain poorly defined. The orphan G protein-coupled receptor 107 (GPR107) mediates signal transduction via clathrin-dependent endocytosis. Here, we report that upregulation of GPR107 in psoriatic keratinocytes promotes both cell proliferation and the secretion of chemokines and antimicrobial peptides through BECN1-dependent autophagy. Mechanistically, internalized GPR107 activates the β-arrestin/ERK/NF-κB pathway. This activation not only drives the direct transcription of inflammatory factors but also negatively regulates the expression of E3-ubiquitin ligase CUL3. The reduction of CUL3 decreases K48-linked ubiquitination at K206 of BECN1, preventing its proteasomal degradation. Stabilization of BECN1 facilitates secretory autophagy in psoriatic keratinocytes, further enhancing their proliferation and inflammatory responses. These findings highlight a novel function of GPR107 in psoriasis, and suggest that the integrated β-arrestin/ERK/NF-κB/CUL3/BECN1 axis may serve as a potential therapeutic target for this disease.
- Open Access
- 12 February 2026
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 14 (2) , e70346
GPR108 Negatively Regulates TLR7 Signaling in Imiquimod‐Induced Psoriasiform Dermatitis
Objective: Psoriasis, a common chronic inflammatory skin disease, is characterized by epidermal hyperplasia and inflammatory cell infiltration. While endosomal Toll‐like receptors (TLRs), particularly TLR7, are key drivers of psoriatic exacerbations, the regulatory mechanisms governing TLR7 activity in psoriasis remain incompletely understood. This study aims to investigate the role of G protein‐coupled receptor 108 (GPR108) in regulating TLR7 activity during imiquimod (IMQ)‐induced psoriasiform dermatitis. Methods: We established IMQ‐induced psoriasiform lesions in Gpr108 ‐null mice, as well as IMQ‐treated GPR108‐deficient keratinocyte and macrophage models. The psoriasis‐like phenotype was assessed in vivo using PASI scoring and H&E staining. Protein expression was examined by Western blotting, immunohistochemistry, and immunofluorescence. Additionally, RNA‐seq and flow cytometric analyses were performed to verify the involvement of the TLR7/NF‐κB signaling in regulating GPR108‐deficient macrophage polarization. Results: We found that Gpr108 deficiency exacerbates IMQ‐induced psoriatic lesions in mice. Mechanistically, GPR108 deficiency enhances TLR7/MyD88/NF‐κB signaling in both keratinocytes and macrophages following imiquimod stimulation. This increased TLR7 activation promotes keratinocyte hyperproliferation and dysregulated differentiation, and alters the M1/M2 macrophage balance, leading to elevated production of cytokines, including TNF‐α and IL‐6. Conclusion: GPR108 functions as a negative regulator of TLR7 signaling in psoriasis.
- 12 February 2026
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 14 (2) , e70346
Open AccessGPR108 Negatively Regulates TLR7 Signaling in Imiquimod‐Induced Psoriasiform Dermatitis
Objective: Psoriasis, a common chronic inflammatory skin disease, is characterized by epidermal hyperplasia and inflammatory cell infiltration. While endosomal Toll‐like receptors (TLRs), particularly TLR7, are key drivers of psoriatic exacerbations, the regulatory mechanisms governing TLR7 activity in psoriasis remain incompletely understood. This study aims to investigate the role of G protein‐coupled receptor 108 (GPR108) in regulating TLR7 activity during imiquimod (IMQ)‐induced psoriasiform dermatitis. Methods: We established IMQ‐induced psoriasiform lesions in Gpr108 ‐null mice, as well as IMQ‐treated GPR108‐deficient keratinocyte and macrophage models. The psoriasis‐like phenotype was assessed in vivo using PASI scoring and H&E staining. Protein expression was examined by Western blotting, immunohistochemistry, and immunofluorescence. Additionally, RNA‐seq and flow cytometric analyses were performed to verify the involvement of the TLR7/NF‐κB signaling in regulating GPR108‐deficient macrophage polarization. Results: We found that Gpr108 deficiency exacerbates IMQ‐induced psoriatic lesions in mice. Mechanistically, GPR108 deficiency enhances TLR7/MyD88/NF‐κB signaling in both keratinocytes and macrophages following imiquimod stimulation. This increased TLR7 activation promotes keratinocyte hyperproliferation and dysregulated differentiation, and alters the M1/M2 macrophage balance, leading to elevated production of cytokines, including TNF‐α and IL‐6. Conclusion: GPR108 functions as a negative regulator of TLR7 signaling in psoriasis.
- 10 October 2025
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 32 (12) , 1414-1427
GPR107: A key driver of breast cancer invasion and metastasis through collagen IV modulation
Breast cancer is a leading cause of cancer-related death in women, and the development of effective treatments for advanced disease remains a critical challenge. Metastasis, the spread of cancer cells to distant sites, is the major cause of mortality in breast cancer. We identified a novel role for the G protein-coupled receptor 107 (GPR107) in promoting breast cancer invasion and metastasis. Furthermore, we found that GPR107 mediates a reduction in collagen Ⅳ (COL4), a key component of the extracellular matrix (ECM) that normally restricts tumor cell invasion. This reduction in COL4 levels was associated with GPR107 mediating the Clathrin-mediated endocytosis of COL4 from the ECM, an increase in matrix metalloproteinase 2 (MMP2) production to degrade COL4 in the ECM, and a decrease in COL4 production. Mechanistically, we identified GPR107 as a key mediator of the ERK/STAT3 pathway activation through β-arrestin, leading to increased expression of MMP2 and suppression of COL4 gene transcription, effectively promoting invasion and metastasis in breast cancer cells. These findings suggest that GPR107 could serve as a promising biomarker for predicting breast cancer malignancy and a potential therapeutic target for preventing and treating metastatic disease.
- 10 October 2025
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 32 (12) , 1414-1427
GPR107: A key driver of breast cancer invasion and metastasis through collagen IV modulation
Breast cancer is a leading cause of cancer-related death in women, and the development of effective treatments for advanced disease remains a critical challenge. Metastasis, the spread of cancer cells to distant sites, is the major cause of mortality in breast cancer. We identified a novel role for the G protein-coupled receptor 107 (GPR107) in promoting breast cancer invasion and metastasis. Furthermore, we found that GPR107 mediates a reduction in collagen Ⅳ (COL4), a key component of the extracellular matrix (ECM) that normally restricts tumor cell invasion. This reduction in COL4 levels was associated with GPR107 mediating the Clathrin-mediated endocytosis of COL4 from the ECM, an increase in matrix metalloproteinase 2 (MMP2) production to degrade COL4 in the ECM, and a decrease in COL4 production. Mechanistically, we identified GPR107 as a key mediator of the ERK/STAT3 pathway activation through β-arrestin, leading to increased expression of MMP2 and suppression of COL4 gene transcription, effectively promoting invasion and metastasis in breast cancer cells. These findings suggest that GPR107 could serve as a promising biomarker for predicting breast cancer malignancy and a potential therapeutic target for preventing and treating metastatic disease.
- 13 September 2025
- Published by Elsevier in Cellular Signalling
- Vol. 136, 112129
GPR108 deficiency promotes urate-induced renal interstitial fibrosis
- 13 September 2025
- Published by Elsevier in Cellular Signalling
- Vol. 136, 112129
GPR108 deficiency promotes urate-induced renal interstitial fibrosis
- Open Access
- 25 August 2025
- Published by Taylor & Francis in Autophagy Reports
- Vol. 4 (1)
Chaperone-mediated autophagy dysfunction in imiquimod-induced psoriasiform dermatitis
Psoriasis is a chronic inflammatory skin disease characterized by abnormal differentiation and hyperproliferation of epidermal keratinocytes. Autophagy plays a critical role in regulating the functions of immune cells, endothelial cells, and especially keratinocytes, contributing to the pathogenesis of psoriasis. However, the role of chaperone-mediated autophagy (CMA) in psoriatic keratinocytes has not been fully explored. Our study, for the first time, revealed that defective CMA is present in imiquimod (IMQ)-induced psoriasiform lesions. Importantly, activation of CMA significantly attenuated IMQ-induced phenotypes both in vitro and in vivo, including reduced skin lesion severity, decreased keratinocyte proliferation and differentiation, and lower cytokine secretion. Mechanistically, toll-like receptor 7 (TLR7), containing a specific KFERQ-like motif, is a substrate for CMA-mediated degradation. This process modulates IMQ-TLR7 signal activation in keratinocytes. CMA deficiency in psoriasis leads to increased TLR7 levels, which, in turn, enhances TLR7-NF-κB signaling pathway activation, ultimately contributing to dysregulated keratinocyte proliferation, differentiation, and cytokine secretion. This study provides novel evidence that defective CMA is present in IMQ-induced psoriasiform lesions and that CMA activation can attenuate IMQ-induced phenotypes by modulating TLR7 signaling in keratinocytes. These findings highlight the potential of CMA as a therapeutic target for psoriasis.
- 25 August 2025
- Published by Taylor & Francis in Autophagy Reports
- Vol. 4 (1)
Open AccessChaperone-mediated autophagy dysfunction in imiquimod-induced psoriasiform dermatitis
Psoriasis is a chronic inflammatory skin disease characterized by abnormal differentiation and hyperproliferation of epidermal keratinocytes. Autophagy plays a critical role in regulating the functions of immune cells, endothelial cells, and especially keratinocytes, contributing to the pathogenesis of psoriasis. However, the role of chaperone-mediated autophagy (CMA) in psoriatic keratinocytes has not been fully explored. Our study, for the first time, revealed that defective CMA is present in imiquimod (IMQ)-induced psoriasiform lesions. Importantly, activation of CMA significantly attenuated IMQ-induced phenotypes both in vitro and in vivo, including reduced skin lesion severity, decreased keratinocyte proliferation and differentiation, and lower cytokine secretion. Mechanistically, toll-like receptor 7 (TLR7), containing a specific KFERQ-like motif, is a substrate for CMA-mediated degradation. This process modulates IMQ-TLR7 signal activation in keratinocytes. CMA deficiency in psoriasis leads to increased TLR7 levels, which, in turn, enhances TLR7-NF-κB signaling pathway activation, ultimately contributing to dysregulated keratinocyte proliferation, differentiation, and cytokine secretion. This study provides novel evidence that defective CMA is present in IMQ-induced psoriasiform lesions and that CMA activation can attenuate IMQ-induced phenotypes by modulating TLR7 signaling in keratinocytes. These findings highlight the potential of CMA as a therapeutic target for psoriasis.
- Open Access
Humanized Major Histocompatibility Complex Transgenic Mouse Model Can Play a Potent Role in SARS-CoV-2 Human Leukocyte Antigen-Restricted T Cell Epitope Screening
Background: COVID-19, caused by SARS-CoV-2, poses a significant threat to human health. Vaccines designed for T-cell epitopes play an important role in eliminating the virus. However, T cell epitope screening often requires the use of a large number of peripheral blood mononuclear cells (PBMCs) from infected or convalescent patients, and if MHC humanized mice can be used for epitope screening, they will not have to wait for enough PBMCs to be available to screen for epitopes, thus buying time for epitope confirmation and vaccine design. Methods: In this study, we used SARS-CoV-2 BA.5 to infect HLA-A11/DR1, C57BL/6, hACE2 mice, and detected body weight changes, viral load, and pathological changes after infection. Fourteen days after the HLA-A11/DR1 and C57BL/6 mice were immunized against inactivated viruses, IgG antibodies were detected in mouse serum using ELISA, and IFN-γ produced by peptide stimulation of splenocytes was detected by ELISpot. Results: There is no obvious pathogenic phenotype of SARS-CoV-2 infection in HLA-A11/DR1 mice. Specific IgG antibodies were detected in serum after immunization of inactivated virus in both HLA-A11/DR1 and C57BL/6 mice, but specific IFN-γ was detected in splenocytes of HLA-A11/DR1 mice. Conclusions: Although HLA-A11/DR1 mice are unable to replicate the virus effectively in vivo, they are able to generate cellular immune responses after immunization inactivated viruses. Therefore, it can be used as a tool to substitute for human PBMCs in epitope screening, thus shortening the timeliness of T cell epitope screening and obtaining the immunogenicity information of new epitopes in a timely manner.
Open AccessHumanized Major Histocompatibility Complex Transgenic Mouse Model Can Play a Potent Role in SARS-CoV-2 Human Leukocyte Antigen-Restricted T Cell Epitope Screening
Background: COVID-19, caused by SARS-CoV-2, poses a significant threat to human health. Vaccines designed for T-cell epitopes play an important role in eliminating the virus. However, T cell epitope screening often requires the use of a large number of peripheral blood mononuclear cells (PBMCs) from infected or convalescent patients, and if MHC humanized mice can be used for epitope screening, they will not have to wait for enough PBMCs to be available to screen for epitopes, thus buying time for epitope confirmation and vaccine design. Methods: In this study, we used SARS-CoV-2 BA.5 to infect HLA-A11/DR1, C57BL/6, hACE2 mice, and detected body weight changes, viral load, and pathological changes after infection. Fourteen days after the HLA-A11/DR1 and C57BL/6 mice were immunized against inactivated viruses, IgG antibodies were detected in mouse serum using ELISA, and IFN-γ produced by peptide stimulation of splenocytes was detected by ELISpot. Results: There is no obvious pathogenic phenotype of SARS-CoV-2 infection in HLA-A11/DR1 mice. Specific IgG antibodies were detected in serum after immunization of inactivated virus in both HLA-A11/DR1 and C57BL/6 mice, but specific IFN-γ was detected in splenocytes of HLA-A11/DR1 mice. Conclusions: Although HLA-A11/DR1 mice are unable to replicate the virus effectively in vivo, they are able to generate cellular immune responses after immunization inactivated viruses. Therefore, it can be used as a tool to substitute for human PBMCs in epitope screening, thus shortening the timeliness of T cell epitope screening and obtaining the immunogenicity information of new epitopes in a timely manner.
- Open Access
- 11 February 2025
- Published by Springer Nature in Molecular Biomedicine
- Vol. 6 (1) , 1-19
G protein-coupled receptor 107 deficiency promotes development of diabetic nephropathy
Diabetic nephropathy (DN) is characterized by glomerular basement membrane (GBM) thickening, primarily due to the abnormal accumulation of collagen type IV (COL4) in the extracellular matrix (ECM) of podocytes. Podocytes endocytosis is crucial for maintaining COL4 balance and GBM integrity. Previous studies have shown that G protein-coupled receptor 107 (GPR107) facilitates clathrin-dependent transferrin internalization and recycling in murine embryonic fibroblast cells. Therefore, the aim of the study is to investigate the role of GPR107 in regulating COL4 balance within the podocytes ECM and its potential as a therapeutic target for DN. Here, we found a significant decrease in GPR107 expression in renal tissues from DN patients and streptozocin (STZ)-induced DN mice. Furthermore, GPR107-deficient mice with STZ-induced DN exhibited more severe kidney damage, marked by increased GBM thickening and COL4 accumulation. In vitro, GPR107 deficiency under high-glucose conditions promoted COL4 accumulation in the ECM of podocytes due to increased COL4 production and decreased COL4 degradation. Mechanistically, we demonstrated that GPR107 contributes to angiotensin II receptor type 1 (AT1R) internalization through clathrin-mediated endocytosis (CME) in podocytes. Therefore, GPR107 deficiency impairs AT1R internalization, leading to increased membrane-bound AT1R. This, in turn, activates the AT1R/Ca2+ signaling pathway to promote phosphorylation of cAMP-response element-binding protein (CREB), ultimately enhancing COL4 synthesis and inhibiting the expression of matrix metalloproteinase 2 (MMP-2). These findings shed light on new functions of GPR107 in DN and offer new insights into a therapeutic target for DN.
- 11 February 2025
- Published by Springer Nature in Molecular Biomedicine
- Vol. 6 (1) , 1-19
Open AccessG protein-coupled receptor 107 deficiency promotes development of diabetic nephropathy
Diabetic nephropathy (DN) is characterized by glomerular basement membrane (GBM) thickening, primarily due to the abnormal accumulation of collagen type IV (COL4) in the extracellular matrix (ECM) of podocytes. Podocytes endocytosis is crucial for maintaining COL4 balance and GBM integrity. Previous studies have shown that G protein-coupled receptor 107 (GPR107) facilitates clathrin-dependent transferrin internalization and recycling in murine embryonic fibroblast cells. Therefore, the aim of the study is to investigate the role of GPR107 in regulating COL4 balance within the podocytes ECM and its potential as a therapeutic target for DN. Here, we found a significant decrease in GPR107 expression in renal tissues from DN patients and streptozocin (STZ)-induced DN mice. Furthermore, GPR107-deficient mice with STZ-induced DN exhibited more severe kidney damage, marked by increased GBM thickening and COL4 accumulation. In vitro, GPR107 deficiency under high-glucose conditions promoted COL4 accumulation in the ECM of podocytes due to increased COL4 production and decreased COL4 degradation. Mechanistically, we demonstrated that GPR107 contributes to angiotensin II receptor type 1 (AT1R) internalization through clathrin-mediated endocytosis (CME) in podocytes. Therefore, GPR107 deficiency impairs AT1R internalization, leading to increased membrane-bound AT1R. This, in turn, activates the AT1R/Ca2+ signaling pathway to promote phosphorylation of cAMP-response element-binding protein (CREB), ultimately enhancing COL4 synthesis and inhibiting the expression of matrix metalloproteinase 2 (MMP-2). These findings shed light on new functions of GPR107 in DN and offer new insights into a therapeutic target for DN.
- Open Access
Lung-Selective Delivery of mRNA-Encoding Anti-MERS-CoV Nanobody Exhibits Neutralizing Activity Both In Vitro and In Vivo
Background/Objectives: The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is a highly pathogenic virus causing severe respiratory illness, with limited treatment options that are mostly supportive. The success of mRNA technology in COVID-19 vaccines has opened avenues for antibody development against MERS-CoV. mRNA-based antibodies, expressed in vivo, offer rapid adaptability to viral mutations while minimizing long-term side effects. This study aimed to develop a lung-targeted lipid nanoparticle (LNP) system for mRNA-encoding neutralizing nanobodies against MERS-CoV, proposing a novel therapeutic strategy. Methods: An mRNA-encoding nanobody NbMS10 (mRNA-NbMS10) was engineered for enhanced stability and reduced immunogenicity. This mRNA was encapsulated in lung-selective LNPs using microfluidics to form the LNP-mRNA-NbMS10 system. Efficacy was assessed through in vitro assays and in vivo mouse studies, focusing on antigen-binding, neutralization, and sustained nanobody expression in lung tissues. Results: The LNP-mRNA-NbMS10 system expressed the nanobody in vitro, showing strong antigen-binding and significant MERS-CoV pseudovirus neutralization. In vivo studies confirmed selective lung mRNA delivery, with high nanobody expression sustained for up to 24 h, confirming lung specificity and prolonged antiviral activity. Conclusions: Extensive in vitro and in vivo evaluations demonstrate the LNP-mRNA-NbMS10 system’s potential as a scalable, cost-effective, and adaptable alternative to current MERS-CoV therapies. This innovative platform offers a promising solution for preventing and treating respiratory infections, and countering emerging viral threats.
Open AccessLung-Selective Delivery of mRNA-Encoding Anti-MERS-CoV Nanobody Exhibits Neutralizing Activity Both In Vitro and In Vivo
Background/Objectives: The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is a highly pathogenic virus causing severe respiratory illness, with limited treatment options that are mostly supportive. The success of mRNA technology in COVID-19 vaccines has opened avenues for antibody development against MERS-CoV. mRNA-based antibodies, expressed in vivo, offer rapid adaptability to viral mutations while minimizing long-term side effects. This study aimed to develop a lung-targeted lipid nanoparticle (LNP) system for mRNA-encoding neutralizing nanobodies against MERS-CoV, proposing a novel therapeutic strategy. Methods: An mRNA-encoding nanobody NbMS10 (mRNA-NbMS10) was engineered for enhanced stability and reduced immunogenicity. This mRNA was encapsulated in lung-selective LNPs using microfluidics to form the LNP-mRNA-NbMS10 system. Efficacy was assessed through in vitro assays and in vivo mouse studies, focusing on antigen-binding, neutralization, and sustained nanobody expression in lung tissues. Results: The LNP-mRNA-NbMS10 system expressed the nanobody in vitro, showing strong antigen-binding and significant MERS-CoV pseudovirus neutralization. In vivo studies confirmed selective lung mRNA delivery, with high nanobody expression sustained for up to 24 h, confirming lung specificity and prolonged antiviral activity. Conclusions: Extensive in vitro and in vivo evaluations demonstrate the LNP-mRNA-NbMS10 system’s potential as a scalable, cost-effective, and adaptable alternative to current MERS-CoV therapies. This innovative platform offers a promising solution for preventing and treating respiratory infections, and countering emerging viral threats.
- Open Access
- 13 October 2024
- Published by Elsevier in Experimental Gerontology
- Vol. 197, 112609
High glucose-induced senescence contributes to tubular epithelial cell damage in diabetic nephropathy
- 13 October 2024
- Published by Elsevier in Experimental Gerontology
- Vol. 197, 112609
Open AccessHigh glucose-induced senescence contributes to tubular epithelial cell damage in diabetic nephropathy